Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients
ConclusionDespite limitations, these MAIC results suggest that brexu-cel may improve OS and EFS versus currently used therapies in this population.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Chemotherapy | Drugs & Pharmacology | Leukemia | Statistics | Stem Cell Therapy | Stem Cells | Study | Transplants